注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
MeiraGTx Holdings plc是一家综合临床阶段基因治疗公司。该公司专注于三个未满足的医疗需求领域,包括遗传性视网膜疾病(ID),以及大型退行性眼病、严重的口干症和神经退行性疾病。该公司的产品管线包括用于治疗X连锁视网膜色素变性(XLRP)的AAV-RPGR、用于治疗二/三级放射性口干症的AAV-hAQP1、用于治疗帕金森病的AAV-GAD、用于治疗色盲(ACHM)的AAV-CNGB3和AAV-CNGA3。该公司有六个临床开发项目,包括色盲、X-连锁色素性视网膜炎和RPE65缺陷的I/II期临床阶段项目,以及辐射诱发口干症(RIX)的I期临床试验,以及帕金森氏症项目 完成了已公布数据的II期试验。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Chuan He | 51 | - | Member of Scientific Advisory Board |
Michael G. Kaplitt | - | - | Member of Scientific Advisory Board |
Nicole Seligman | 67 | 2019 | Independent Director |
Gregory A. Petsko | - | - | Chairman of Scientific Advisory Board |
Keith Reginald Harris | 70 | 2015 | Independent Chairman of the Board |
Arnold J. Levine | 83 | 2016 | Member of Scientific Advisory Board |
James C. Alwine | - | - | Member of Scientific Advisory Board |
Alexandria Forbes | 58 | 2015 | CEO, President & Director |
Kevin Weeks | - | - | Member of Scientific Advisory Board |
Brian Shoichet | - | - | Member of the Scientific Advisory Board |
Martin Indyk | 71 | 2019 | Independent Director |
Debra Yu | 58 | 2022 | Independent Director |
Stefano Rivella | - | - | Member of Scientific Advisory Board |
Thomas E. Shenk | 76 | 2015 | Independent Director & Member of Scientific Advisory Board |
Neil Mendoza | 63 | 2015 | Independent Director |
Lynne Elizabeth Maquat | - | 2019 | Member of Scientific Advisory Board |
Robert Batey | - | - | Member of Scientific Advisory Board |
Ellen Hukkelhoven | 36 | 2017 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核